1. Innovation is in our genes. SPECT-Guided CT in Bone Scintigraphy SPECT-Guided CT for Evaluating Foci of Increased Bone Metabolism Classified as Indeterminate on SPECT in Cancer Patients W. Römer, A. Nömayr, M Uder, W. Bautz, T. Kuwert University of Erlangen, Germany JNM, Vol. 47, No. 7, July 2006 Retrospective study done using the Siemens Symbia T2 TruePoint SPECTCT system

2. Innovation is in our genes. We see away to... eliminate 90% of indeterminate SPECT oncology scans

3. Innovation is in our genes. Summary  52 bone lesions in 44 patients of known cancer were rated as indeterminate with SPECT alone. Majority of the indeterminate lesions were in ribs and the scapula.  When corresponding SPECTCT images were analyzed, 92% of the indeterminate lesions were classified as definitively benign or definitively malignant based on correlation between SPECT and CT findings. Only 8% (4 lesions out of 52) remained indeterminate after analysis of SPECT·CT images.

4. Innovation is in our genes. Study Results and Conclusion  SPECT-guided CT was able to clarify more than 90% of SPECT findings classified as indeterminate*, thus considerably shortening the diagnostic process.  SPECT-guided CT has the potential to reduce patient radiation exposure, by limiting the CT scan to the body region of interest identified by SPECT. * In an analysis blinded to clinical pretest probability and planar scans.

5. Innovation is in our genes. Proven Outcomes  More than 90% of cancer patients leave the clinic with a definite diagnosis Wolfgang Römer, MD, University Clinic of Nuclear Medicine, Erlangen, Germany Malignant Indeterminate Benign 44 52 28 0 25 50 75 100 125 SPECT Lesions 43 77 SPECTCT 4 SPECT vs. SPECTCT Diagnostic in Oncology

6. Innovation is in our genes. Siemens Molecular Imaging innovation is in our genes.